US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Menopause · Vulvovaginal Atrophy · TXMD
TherapeuticsMD
TherapeuticsMD drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Boca Raton, USA HQ
53 Employees
Public company Type
TXMD · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boca Raton, USA
- Employees
- 53
- Programs
- 6
- Drugs
- 6
- Patents
- 0
TherapeuticsMD pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
TherapeuticsMD drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
oxybutynin
Genito-urinary system and sex hormones (G04)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M2.
- Target
- Muscarinic acetylcholine receptor M2
- Mechanism
- Muscarinic acetylcholine receptor M2 antagonist
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist